Compass Ion Advisors LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)

Compass Ion Advisors LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 55.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,295 shares of the biopharmaceutical company’s stock after purchasing an additional 8,677 shares during the quarter. Compass Ion Advisors LLC’s holdings in Pfizer were worth $645,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC purchased a new stake in Pfizer during the 4th quarter worth about $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer in the 4th quarter worth about $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the 4th quarter worth about $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer in the 4th quarter worth about $31,000. Finally, Curio Wealth LLC acquired a new stake in Pfizer in the 4th quarter worth about $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $26.31 on Wednesday. The stock’s 50 day moving average price is $26.21 and its 200 day moving average price is $27.09. The firm has a market capitalization of $149.09 billion, a PE ratio of 18.66, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.10 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on PFE. Truist Financial decreased their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Citigroup decreased their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Bank of America reissued a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Finally, StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.